CIK 0001691082 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
LB PHARMACEUTICALS INC
Sign in to watch- Ticker
- LBRX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 917-450-6581
- Business address
- 575 MADISON AVENUE, NEW YORK, NY, 10022
- Former names
- LB PHARMACEUTICALS INC.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-10-09 | Kozauer Susan Gani Chief Medical Officer | Grant or award · Emplopyee Stock Option (Right to Buy) | +200,000 | 200,000 | ||
| 2026-10-09 | Miller Joseph M Chief Financial Officer | Grant or award · Emplopyee Stock Option (Right to Buy) | +200,000 | 200,000 | ||
| 2026-07-30 | Deep Track Biotechnology Master Fund, Ltd. 10% owner | Purchase · Pre-Funded Warrants (Right to Buy) | +286,205 | $34.94 | $10.0M | 664,649 |
| 2026-06-03 | Luse Rebecca Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2026-06-03 | Lenz Robert A. Director | Grant or award · Stock Option (Right to Buy) | +12,500 | 12,500 | ||
| 2026-06-03 | Kane William P Jr Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2026-06-03 | Hemrajani Rekha Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2026-06-03 | Nussbaum Ran Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2026-06-03 | Garland J. Scott Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2026-06-03 | RUFFOLO ROBERT R Director | Grant or award · Stock Option (Right to Buy) | +10,000 | 10,000 | ||
| 2026-03-06 | Lenz Robert A. Director | Grant or award · Stock Option (Right to Buy) | +20,000 | 20,000 | ||
| 2026-02-06 | Deep Track Biotechnology Master Fund, Ltd. 10% owner | Purchase · Pre-Funded Warrants (Right to Buy) | +378,444 | $21.17 | $8.0M | 378,444 |
| 2026-02-06 | Deep Track Biotechnology Master Fund, Ltd. 10% owner | Purchase · Pre-Funded Warrants (Right to Buy) | +93,925 | $21.17 | $2.0M | 93,925 |
| 2025-12-10 | Pai Panandiker Kaya Kamlesh Chief Commercial Officer | Grant or award · Employee Stock Option (Right to Buy) | +195,000 | 195,000 | ||
| 2025-09-12 | Deep Track Biotechnology Master Fund, Ltd. 10% owner | Conversion | +686,138 | 686,138 | ||
| 2025-09-12 | Deep Track Biotechnology Master Fund, Ltd. 10% owner | Purchase | +2,000,000 | $15.00 | $30.0M | 2,686,138 |
| 2025-09-12 | Deep Track Biotechnology Master Fund, Ltd. 10% owner | Purchase | +666,666 | $15.00 | $10.0M | 666,666 |
| 2025-09-12 | Deep Track Biotechnology Master Fund, Ltd. 10% owner | Conversion · Series C Preferred Stock | −16,666,667 | 0 | ||
| 2025-09-12 | Pontifax Management 4 G.P. (2015) Ltd. 10% owner | Conversion | +411,681 | 411,681 | ||
| 2025-09-12 | Pontifax Management 4 G.P. (2015) Ltd. 10% owner | Purchase | +1,000,000 | $15.00 | $15.0M | 1,411,681 |
Page 1 of 5 · 84 trades